Global Sleep Apnea Market Analysis & Forecast to 2023-2033
08 nov. 2023 04h08 HE
|
Research and Markets
Dublin, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Sleep Apnea Market Analysis & Forecast to 2023-2033: Market By Product; By End-user; and by Region" report has been added to ...
Apnimed to Participate in Upcoming November Investor Conferences
06 nov. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Global Sleep Apnea Implants Market 2023-2027: Increasing Prevalence of Sleep Apnea and Respiratory Disorders Drives Growth
03 nov. 2023 06h08 HE
|
Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Sleep Apnea Implants Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.The sleep apnea implants market is forecasted...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
31 oct. 2023 20h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
18 oct. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed to Participate in Upcoming October Investor Conferences
11 oct. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 oct. 2023 08h00 HE
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Global Sleep Apnea Diagnostic System Industry Research Report 2023-2030 - AI Innovations Transform Sleep Disorder Diagnosis in Booming Market
28 sept. 2023 10h28 HE
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Sleep Apnea Diagnostic System Market, By Product Type, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030"...
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 sept. 2023 05h30 HE
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...